All In Biotech

Drug Trial Radar · NCT03161652

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

Clinical Trial to Evaluate the Safety and Efficacy of Levosulpiride to Improve Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 24, 2017

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Carmen ClappAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Instituto Mexicano de Oftalmologia (IMO); Universidad Autónoma de Querétaro; General Hospital Nuremberg & Paracelsus Medical University Nuremberg; Instituto de la Retina del Bajio SC (INDEREB); Instituto de Neurobiología, Universidad Nacional Autonoma de Mexico (UNAM)
First posted
May 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of levosulpiride to improve retinal alterations due to diabetic macular edema and diabetic retinopathy

Conditions

  • Diabetic Macular Edema
  • Diabetic Retinopathy

Interventions

  • DME lactose pillDrug

    Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.

  • DME levosulpirideDrug

    Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.

  • DR lactose pillDrug

    Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.

  • DR levosulpirideDrug

    Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.

  • DR vitrectomy lactose pillDrug

    Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.

  • DR vitrectomy levosulpirideDrug

    Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.

  • DME plus ranibizumab lactose pillDrug

    Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.

  • DME plus ranibizumab levosulpirideDrug

    Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual acuityTime frame: 5 minutes
  2. Retinal thicknessTime frame: Pupils are dilated (eye drops) for 10 to 15 minutes and optical coherence tomography (OCT) images recorded during 5 minutes.
  3. Retinal hard exudates and hemorrhagesTime frame: Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded during 5 minutes
  4. Retinal microaneurisms, leakage area, cotton-wool spots, venous beading, microvascular and vascular abnormalitiesTime frame: Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded before and at different times (0.5 to 5 minutes) after fluorescein injection.
  5. Prolactin serum levelsTime frame: 1-2 minutes (duration of blood withdrawal)
  6. Prolactin vitreous levelsTime frame: 2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)
  7. Vasoinhibin vitreous levelsTime frame: 2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Mexicano de Oftalmologia (IMO)

    Querétaro City, Querétaro, Mexico · Recruiting

  • Instituto de la Retina del Bajio SC (INDEREB)

    Querétaro City, Querétaro, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.